Cannabis Fun Club in Russia

The renewed debate over the medicinal use of marijuana has provided the impetus for the development of a suitable aerosol formulation of cannabinoids. The objectives of this study were to (1) develop and characterize the physical properties of an aerosol formulation of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the primary psychoactive constituent of marijuana; and (2) determine the pharmacological effects of inhaled cannabinoids in mice. Aerosol device , spraying small particles (SPAG) used For generation aerosol . All particles were small in diameter, so they were small enough to penetrate deep into the lungs. After mice were inhaled with Delta(9)-THC, anti-pain effects were detected that were dependent on the concentration and time of exposure to the proposed dose of Delta(9)-THC of 1.8 mg/kg. On the other hand, inhalation of Delta(9)-THC did not cause two other indicators of cannabinoid activity, hypothermia and decreased spontaneous motor activity. Anti-pain effects appeared five minutes after inhalation and lasted for about 40 minutes. Cannabinoid receptor antagonists N -( piperidin -1- yl )-5-(4- chlorophenyl )-1-(2, 4- dichlorophenyl )-4- methyl -1 H - pyrazole -3- carboxamide HCl ( S.R. 141716 A ), but not naloxone, blocked these anti-pain effects ( AD (50)=0.09 mg/kg), indicating a cannabinoid receptor mechanism of action. Similarly, the effect of inhalation on a water-soluble cannabinoid analogue, 3-(5'- cyano -eleven dimethylheptyl )-1-(4- N - morpholinobutyroloxy )- Delta (8)- tetrahydrocann abinol ( O -1057), generated antinociception, which was blocked S.R. 141716 A These results demonstrate that it is feasible to establish the production of an aerosol form of cannabinoids for medical use, for the treatment of people.